Tag Archives: HTA
By Guest Blogger | Published: July 17, 2014
By Philip Ward, Applied Clinical Trials. The European Medicines Agency (EMA) has insisted that the concerns raised about its scientific advice given to pharmaceutical companies stem from a flawed understanding of the activities of the agency and its partners in this area.
By Clark Herman | Published: July 3, 2013
PharmaFutures’ Pathways to Value: Pharma in a Changing World explains how the industry may move forward to combine business imperatives and social mandates through new strategies for determining value and reimbursement for medicines. The study determines that collaboration across three fronts is needed to ensure that value is recognized and adapted over time, taking into […]
By Guest Blogger | Published: March 27, 2013
By Reflector, Brussels correspondent. Any complacency that the world of healthcare might be feeling about advances in the ability to treat patients suffered a head-on assault in Dublin, Ireland, last week, at a conference organized under the auspices of the Irish Presidency of the European Union and featuring a galaxy of Irish and European stars […]
By Guest Blogger | Published: July 27, 2011
Reflector finds some surprising common ground in what should be two very different HTA reports. Just like with buses, you wait for ages for an international review of health technology assessment to come along, then two turn up at once.
By Guest Blogger | Published: April 22, 2011
Cameron McClearn looks at how Washington State’s approach to health care value is beginning to influence the rest of the country. Many trends start on the West Coast and migrate to the rest of the nation. The Washington State health care system is worth watching as officials evaluate the economic value of medical treatments for […]